Pediatric Infectious Disease Journal:
Preparing for the Scale-up of Rotavirus Vaccine Introduction in Africa: Establishing Surveillance Platforms to Monitor Disease Burden and Vaccine Impact
Mwenda, Jason M. PhD*; Tate, Jacqueline E. PhD†; Steele, A. Duncan PhD‡; Parashar, Umesh D. MB BS, MPH†
From the *World Health Organization, Regional Office for Africa, Brazzaville, Republic of Congo, †National Center for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia; and ‡Bill & Melinda Gates Foundation, Seattle, Washington.
Accepted for publication September 25, 2013.
The findings and conclusions of this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention (CDC) and World Health Organization.
The authors have no conflicts of interest to disclose. Financial support listed in the Acknowledgments.
Address for correspondence: Jason M. Mwenda, PhD, New Vaccines Surveillance, Immunization, Vaccines and Emergencies Cluster, WHO Regional Office for Africa, PO Box 06 Djoue, Brazzaville, Congo Republic. E-mail: email@example.com.
Countries in Africa have begun introducing rotavirus vaccines in their national immunization programs, and wide-scale rollout across the continent is expected during the next few years. In preparation for vaccine introduction, many countries initiated surveillance for rotavirus and other studies to document disease burden, to describe the epidemiology and to monitor circulating rotavirus strains in Africa. In addition, 2 countries sought to systematically investigate cases of intussusception, a rare adverse event that has been associated with rotavirus vaccines in some settings. The ongoing surveillance provided data that will serve as a baseline against which the impact of rotavirus vaccines in Africa can be assessed.
Rotavirus, the most common cause of severe diarrhea among children <5 years of age worldwide, is responsible for significant mortality and morbidity among children in Africa. In 2008, of the estimated 453,000 global deaths from rotavirus diarrhea in children <5 years of age, more than half (N = 230,000) occurred in African children.1 Five of the 10 countries worldwide with the greatest absolute number of rotavirus deaths and 9 of the 10 countries with the highest rate of rotavirus mortality are in Africa.1 The African Rotavirus Surveillance Network coordinated by the World Health Organization (WHO) Regional Office for Africa has played an important role in documenting the rotavirus disease burden in Africa. Established in 2006 with 4 countries conducting rotavirus surveillance, the network has expanded over subsequent years. By 2013, 22 countries in sub-Saharan Africa were conducting rotavirus surveillance using a standardized protocol developed by WHO.2 Similarly, in North Africa, 4 countries participated in the rotavirus surveillance network coordinated by the Eastern Mediterranean Regional Office and follow the same WHO protocol.
Currently, 2 live, attenuated, oral vaccines, a pentavalent bovine-human reassortant vaccine (RV5; RotaTeq; Merck and Co, Inc, West Point, PA) and a monovalent vaccine (RV1; Rotarix; GSK Biologicals, Rixensart, Belgium) based on a human rotavirus strain, are licensed and prequalified by WHO and are available for introduction into national immunization programs of countries.3,4 Clinical trials conducted in 5 countries in Africa found that these vaccines were 49%–72% efficacious in preventing severe gastroenteritis in African children during the first year of life.5,6 While the efficacy of these oral vaccines in the African clinical trials was lower than the 85%–98% efficacy observed in clinical trials carried out in Europe and America,3,4 the vaccine will prevent a greater number of deaths due to rotavirus diarrhea in Africa and other high disease burden settings than in low disease burden, developed countries because of the substantially greater rotavirus mortality rates in Africa. Recognizing this, in 2009, WHO recommended the use of rotavirus vaccines in all countries globally and particularly those countries with high mortality due to diarrhea.7
In 2009, South Africa became the first African country to introduce rotavirus vaccine into its national immunization program followed by Morocco which introduced in 2010. In 2011, the Republic of Sudan became the first Global Alliance for Vaccines and Immunization (GAVI)-eligible country in Africa to introduce rotavirus vaccine with the support of WHO and partners. By the end of July 2013, 6 additional countries (Ghana, Rwanda, Botswana, Malawi, Tanzania and The Gambia) had introduced rotavirus vaccine into their national immunization programs and 1 country, Zambia, introduced rotavirus vaccine in 1 province as part of a demonstration project (Fig. 1). In addition to these 10 countries that introduced rotavirus vaccine, 13 more African countries have been approved to introduce rotavirus vaccines with the support of GAVI by the end of 2014, but this will depend on the availability of rotavirus vaccines and actions to overcome other logistical issues such as cold chain expansion. The rapid introduction of rotavirus vaccines in low-income African countries has been facilitated by financial support for vaccine purchase from the GAVI Alliance for eligible countries with a GNI of US$1550 per capita or below. These countries are required to co-finance for a full dose of rotavirus vaccine for each child, and the remainder of the price is subsidized by the GAVI Alliance.
The GAVI Alliance has also provided financial support to WHO for rotavirus surveillance networks in Africa and in other regions of the world, both to establish baseline data on rotavirus disease burden and viral strain diversity, to coordinate capacity building activities and to help monitor vaccine impact after introduction. This supplement highlights data on rotavirus disease burden in Africa before rotavirus vaccine introduction. The studies included in this supplement describe the baseline rotavirus disease burden and strain diversity in many African countries, as well as characterize the epidemiology of intestinal intussusception, a rare adverse event associated with rotavirus vaccine.8 As rotavirus vaccine is rolled out across Africa, these studies coupled with ongoing sentinel surveillance will provide important data against which the impact of rotavirus vaccine can be measured. Notably, all these early countries (except Botswana) that have introduced rotavirus vaccine in their expanded program on immunization have established robust hospital-based sentinel site surveillance infrastructure that can be used to evaluate impact and safety of rotavirus vaccines.
ROTAVIRUS DISEASE BURDEN
Sentinel hospital-based surveillance in many countries showed that rotavirus accounted for 21%–56% of diarrheal hospitalizations among children <5 years of age in Africa during the pre-vaccine era.9–18 A population-based surveillance study at 1 site in Kenya estimated that rotavirus diarrhea resulted in 565 hospitalizations per 100,000 children <5 years of age.11 In many countries, rotavirus hospitalizations occurred most frequently in young children, with children <1 year of age accounting for a majority of all rotavirus hospitalizations in Ethiopia (56%), Sudan (61%), Ghana (64%), Uganda (65%), Zimbabwe (66%) and Nigeria (77%)9,10,13–15,17 (Fig. 2). Conversely, in Mauritius, only 21% of rotavirus hospitalizations occurred among children <1 year of age, but this may be due to differential treatment-seeking behaviors by age with children <1 year of age potentially more likely to seek care at private, nonsurveillance hospitals than older children.16 A birth cohort study in Egypt found that 40% of children had at least 1 episode of rotavirus by their second birthday.19 Given this high disease burden, particularly among young children, rotavirus vaccines will likely have a rapid and substantial impact on diarrheal disease when introduced into the national immunization programs of these countries.
In-hospital deaths due to rotavirus and diarrhea were captured by most of the surveillance sites although the numbers of deaths were small. These numbers likely underestimate the true rotavirus mortality as children who are brought for care in a timely manner and are appropriately treated usually have good outcomes. However, many deaths due to diarrhea occur in the community and are not captured by hospital-based surveillance. Furthermore, hospitalized children recruited into surveillance are not followed after discharge but have been shown to have higher rates of mortality than healthy children.20 A study in Kenya that used verbal autopsy data for all deaths estimated that 140 rotavirus-associated deaths per 100,000 children <5 years of age occurred annually.11 Given that rotavirus vaccines have proven effective in preventing mortality from diarrhea in Latin American countries that were early vaccine adopters,21–23 they will help prevent deaths among African children who have severe diarrhea and are unable to access appropriate and/or timely care.
Rotavirus was also detected among children seeking care in outpatient settings. In Kenya, 12%–20% of outpatient visits for diarrhea among children <5 years of age were due to rotavirus.11,24 Rotavirus was also detected in older children and adults who sought outpatient care for diarrhea in Kenya. While these populations had lower rates of disease than among young children, introduction of rotavirus vaccine could have a broad impact if these groups indirectly benefit from reduced circulation of rotavirus in the community. Indirect benefits have been observed in several high-income and middle income countries using rotavirus vaccine in their national immunization programs, and as vaccines are rolled out in Africa,25–27 evaluations should specifically assess whether such effects occur in the high disease burden African setting.
Rotavirus was detected year-round in Africa, but disease peaked during the cool, dry months in most countries. However, some variability in the seasonal pattern occurred. For example, Ghana and Mauritius each reported that rotavirus peaked outside the typical season during 1 year of their multiyear surveillance periods.10,16 Uganda reported 2 peaks per year both during the rainy season and Sudan also reported 2 peaks in rotavirus disease.14,15
In addition to active surveillance, routinely collected health data can provide insight into the burden and seasonality of diarrhea and rotavirus disease. In Rwanda, data routinely collected through the Health Management Information System showed that diarrheal disease was highly seasonal with hospitalizations and outpatient visits peaking during the cool, dry months, the same months when rotavirus disease peaks in Rwanda.28 Thus, consistent, high-quality, routinely collected data can provide another platform against which to gauge the broader impact of rotavirus vaccine on the national diarrhea disease burden, and one would expect this impact to be greater during the months of the year with peak rotavirus activity.
ROTAVIRUS STRAIN DIVERSITY
Tremendous diversity of circulating rotavirus strains was observed in sub-Saharan Africa. While G1P was the most frequently reported strain detected during 2007 to 2011, it was found in only 18% of rotavirus-positive samples from 16 countries followed by G9P (12%) and G2P (9%).29 There was some variability between regions within Africa, but each region had a wide range of circulating strains that included mixed infections and untypeable strains. Some countries also reported substantial year-to-year variability in the predominant strain. For example, in Mauritius, G3P accounted for 89% of circulating strains in 2008, G4P for 76% of strains in 2009 and G1P for 90% of strains in 2010.17 Other countries, such as Ethiopia, Kenya, Uganda and The Gambia, reported a board range of circulating strains each year with no one strain accounting for >50% of strains detected.9,12,15,30
While these findings support earlier studies showing that diverse rotavirus strains circulate in African populations, it is reassuring to note that clinical trials and post-licensure evaluations of both available rotavirus vaccines demonstrate good protection against rotavirus disease caused by various strains, including those that do not match either the G or P type or both for the strains included in the vaccines.3–6,31–34 Nevertheless, as vaccines are implemented in national programs, monitoring their impact on circulating rotavirus strains will be important.
While pre-licensure trials did not show a link between current rotavirus vaccines and intussusception,3,4 these vaccines have been associated with a low-level risk of intussusception during post-licensure surveillance in some high-income and middle income countries, including the United States, Australia, Mexico and Brazil.8,35–37 Whether the vaccines will be associated with intussusception in low-income countries and, if so, whether the level of risk will differ in these settings from high-income and middle income countries are unclear.
While data on intussusception in Africa are sparse, in preparation for vaccine introduction, researchers in Zambia and Rwanda reviewed medical records for children hospitalized with intussusception.38,39 Many cases occurred among infants <1 year of age, and almost all required surgical intervention. Delays in presentation were common with 56% of children in Zambia and 70% of children in Rwanda presenting over 3 days after symptom onset. Delays in access to care may have contributed to poor outcomes. The case fatality rate was 34% in Zambia and 28% in Rwanda. Similarly, a case report from South Africa highlights the importance of sensitizing African doctors to consider intussusception in their differential diagnosis of cases presenting with the classic triad of symptoms for intussusception (vomiting, abdominal pain and currant jelly stools) to ensure that intussusception cases are identified and treated promptly.40
Active rotavirus surveillance networks, such as those highlighted in the supplement, will play an important role in monitoring the impact of rotavirus vaccine after its introduction. First, the data collected through these platforms can serve as a baseline against which changes in the proportion of diarrhea hospitalizations due to rotavirus can be measured and changes in the age distribution of rotavirus cases, seasonality of rotavirus disease and circulating strains can be monitored. Similarly, high-quality, routinely collected health information system data on all-cause diarrhea hospitalizations can also be used to monitor the impact of rotavirus vaccine at the broader country level to estimate the number of hospitalizations and outpatient visits prevented by vaccine introduction. Second, rotavirus causes disease in older children and adults although at lower levels than in young children. Studies in the Unites States and Australia have shown a decrease of diarrheal disease in these populations after rotavirus vaccine introduction into the infant immunization schedule, suggesting that unvaccinated children and adults may be indirectly protected by reduced circulation of disease among young children.25–27 Monitoring rates of disease in these populations are important to understand the full impact of the vaccine. Finally, as rotavirus vaccines have been associated with a low-level risk of intussusception in some settings, monitoring the risk of intussusception after rotavirus vaccine introduction will be an important priority for countries introducing rotavirus vaccine. Africa has one of the greatest burdens of rotavirus disease globally, and rotavirus vaccines are poised to have a substantial impact across the continent. The data reported in this supplement highlight the critical need to establish and maintain robust surveillance that can be used to document the impact of newly introduced vaccines in national immunization programs.
The authors acknowledge GAVI Alliance for financial support to WHO; support from national expanded program for immunization Managers; national Ministries of Health; WHO EPI/surveillance officers; Inter Country Support teams (IST) including the Data Managers and country sentinel site implementation teams coordinating rotavirus Surveillance at different levels and support from Centers for Disease Prevention and Control.
1. Tate JE, Burton AH, Boschi-Pinto C, et al.WHO-coordinated Global Rotavirus Surveillance Network. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:136–141
2. Mwenda JM, Ntoto KM, Abebe A, et al. Burden and epidemiology of rotavirus diarrhea in selected African countries: preliminary results from the African Rotavirus Surveillance Network. J Infect Dis. 2010;202(suppl):S5–S11
3. Vesikari T, Matson DO, Dennehy P, et al.Rotavirus Efficacy and Safety Trial (REST) Study Team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354:23–33
4. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al.Human Rotavirus Vaccine Study Group. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354:11–22
5. Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;376:606–614
6. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med. 2010;362:289–298
7. Rotavirus. vaccines: an update. . Releve epidemiologique hebdomadaire/Section d’hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record/Health Section of the Secretariat of the League of Nations. Wkly Epidemiol Rec. 2009;84:533–540
8. Patel MM, López-Collada VR, Bulhões MM, et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med. 2011;364:2283–2292
9. Abebe A, Teka T, Kassa T, et al. Hospital-based surveillance for rotavirus gastroenteritis in children younger than 5 years of age in Ethiopia: 2007–2011. Pediatr Infect Dis J. 2014;33 (Suppl 1):S28–S33
10. Enweronu-Laryea CC, Sagoe KWC, Mwenda JM, et al. Severe acute rotavirus gastroenteritis in children less than 5 years in southern Ghana: 2006–2011. Pediatr Infect Dis J. 2014;33 (Suppl 1):S9–S13
11. Khagayi S, Burton DC, Onkoba R, et al. High burden of rotavirus gastroenteritis in young children in rural Western Kenya, 2010–2011. Pediatr Infect Dis J. 2014;33 (Suppl 1):S34–S40
12. Kiulia NM, Nyaga MM, Seheri ML, et al. Rotavirus G and P types circulating in the Eastern region of Kenya: predominance of G9 and emergence of G12 genotypes. Pediatr Infect Dis J. 2014;33 (Suppl 1):S85–S88
13. Mukaratirwa A, Berejena C, Nziramasanga P, et al. Epidemiologic and genotypic characteristics of rotavirus strains detected in children less than 5 years of age with gastroenteritis treated at 3 pediatric hospitals in Zimbabwe During 2008–2011. Pediatr Infect Dis J. 2014;33 (Suppl 1):S45–S48
14. Mustafa A, Makki A, Siddig O, et al. Baseline burden of rotavirus disease in Sudan to monitor the impact of vaccination. Pediatr Infect Dis J. 2014;33 (Suppl 1):S23–S27
15. Odiit A, Mulindwa A, Nalumansi E, et al. Rotavirus prevalence and genotypes among children younger than 5 years with acute diarrhea at Mulago National Referral Hospital, Kampala, Uganda. Pediatr Infect Dis J. 2014;33 (Suppl 1):S41–S44
16. Pursem VN, Peeroo C, Mangar T, et al. Epidemiology of rotavirus diarrhea and diversity of rotavirus strains among children less than 5 years of age with acute gastroenteritis in Mauritius: June 2008 to December 2010. Pediatr Infect Dis J. 2014;33 (Suppl 1):S49–S53
17. Tagbo BN, Mwenda JM, Armah G, et al. Epidemiology of rotavirus diarrhea among younger than 5 years in Enugu, South East, Nigeria. Pediatr Infect Dis J. 2014;33 (Suppl 1):S19–S22
18. Tsolenyanu E, Seheri M, Dagnra A, et al. Surveillance for rotavirus gastroenteritis in children less than 5 years of age in Togo. Pediatr Infect Dis J. 2014;33 (Suppl 1):S14–S18
19. Ahmed SF, Klena JD, Mansour AM, et al. Rotavirus genotypes associated with acute diarrhea in Egyptian infants. Pediatr Infect Dis J. 2014;33 (Suppl 1):S62–S68
20. Kotloff KL, Nataro JP, Blackwelder WC, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet. 2013;382:209–222
21. Richardson V, Parashar U, Patel M. Childhood diarrhea deaths after rotavirus vaccination in Mexico. N Engl J Med. 2011;365:772–773
22. do Carmo GM, Yen C, Cortes J, et al. Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis. PLoS Med. 2011;8:e1001024
23. Lanzieri TM, Linhares AC, Costa I, et al. Impact of rotavirus vaccination on childhood deaths from diarrhea in Brazil. Int J Infect Dis. 2011;15:e206–e210
24. Breiman RF, Cosmas L, Audi A, et al. Use of population-based surveillance to determine the incidence of rotavirus gastroenteritis in an urban slum and a rural setting Kenya. Pediatr Infect Dis J. 2014;33 (Suppl 1):S54–S61
25. Clarke MF, Davidson GP, Gold MS, et al. Direct and indirect impact on rotavirus positive and all-cause gastroenteritis hospitalisations in South Australian children following the introduction of rotavirus vaccination. Vaccine. 2011;29:4663–4667
26. Lopman BA, Curns AT, Yen C, et al. Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis. 2011;204:980–986
27. Payne DC, Staat MA, Edwards KM, et al.New Vaccine Surveillance Network (NVSN). Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US Counties, 2006-2009. Clin Infect Dis. 2011;53:245–253
28. Ngabo F, Gatera M, Karema C, et al. Can routinely collected national data on childhood morbidity and mortality from diarrhea be used to monitor health impact of rotavirus vaccination in Africa? Examination of pre-vaccine baseline data from Rwanda. Pediatr Infect Dis J. 2014;33 (Suppl 1):S89–S93
29. Seheri M, Nemarude AL, Peenze I, et al. Update of rotavirus strains circulating in Africa from 2007 through 2011. Pediatr Infect Dis J. 2014;33 (Suppl 1):S76–S84
30. Kwambana BA, Ikumapayi UN, Sallah N, et al. High genotypic diversity among rotavirus strains infecting Gambian children. Pediatr Infect Dis J. 2014;33 (Suppl 1):S69–S76
31. Yen C, Figueroa JR, Uribe ES, et al. Monovalent rotavirus vaccine provides protection against an emerging fully heterotypic G9P rotavirus strain in Mexico. J Infect Dis. 2011;204:783–786
32. Correia JB, Patel MM, Nakagomi O, et al. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P strains in Brazil. J Infect Dis. 2010;201:363–369
33. Justino MC, Linhares AC, Lanzieri TM, et al. Effectiveness of the monovalent G1P human rotavirus vaccine against hospitalization for severe G2P rotavirus gastroenteritis in Belém, Brazil. Pediatr Infect Dis J. 2011;30:396–401
34. Patel MM, Patzi M, Pastor D, et al. Effectiveness of monovalent rotavirus vaccine in Bolivia: case-control study. BMJ. 2013;346:f3726
35. Buttery JP, Danchin MH, Lee KJ, et al.PAEDS/APSU Study Group. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine. 2011;29:3061–3066
38. Mpabalwani EM, Chitambala P, Chibumbya JN, et al. Intussusception incidence rates in 9 Zambian Hospitals, 2007–2011: pre–rotavirus vaccine introduction. Pediatr Infect Dis J. 2014;33 (Suppl 1):S94–S98
39. Ngendahayo E, Bonane A, Ntakiyiruta G, et al. Preparing for safety monitoring after rotavirus vaccine implementation: a retrospective review of intussusception cases among children at a large teaching hospital in Rwanda, 2009–2012. Pediatr Infect Dis J. 2014;33 (Suppl 1):S99–S103
40. Mwenda JM, Loveland JA, Jugmohan B, Singh S. High index of suspicion of intussusception in an 8-month South African child: a case report. Pediatr Infect Dis J. 2014;33 (Suppl 1):S104–S106
rotavirus vaccine; surveillance; Africa
© 2014 by Lippincott Williams & Wilkins, Inc.
What does "Remember me" mean?
By checking this box, you'll stay logged in until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
Highlight selected keywords in the article text.
Data is temporarily unavailable. Please try again soon.